Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02246127 | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor(SEQTOR) | completed | Phase 3 | 141 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 8 | May 11, 2025 | clinicaltrials |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | completed | Phase 4 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| May 9, 2025 |
| clinicaltrials |
| NCT06456723 | Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.(FETONET) | completed | Phase 1 / Phase 2 | 56 | Imperial College LondonOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT04584866 | Semi-sitting Versus Supine Position in Endoscopic Skull Base Surgery(PosESS) | completed | N/A | 54 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03667092 | Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor(GENEBIOLuNET) | completed | N/A | 47 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04986085 | Nutrition in Gastroenteropancreatic Neuroendocrine Tumor(NUTRIGETNE) | completed | — | 399 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02348749 | 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06853457 | A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases | completed | — | 257 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 3, 2025 | clinicaltrials |
| NCT02795858 | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | completed | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04438304 | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | completed | Phase 2 | 45 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05246319 | Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors(TEGRELE) | completed | — | 50 | Laurent BRUNAUDOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05680675 | Dual-Tracer Theranostic PET | completed | N/A | 50 | University of UtahOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02691078 | Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors | completed | Phase 2 | 15 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05013957 | Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study(NEMESIs) | completed | — | 32 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04696042 | Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs(AIM-NETs) | completed | — | 71 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT06790056 | Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)(DEBL) | completed | — | 50 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02736500 | Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors(LuX) | completed | Phase 1 / Phase 2 | 39 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03980925 | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | completed | Phase 2 | 37 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03095274 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin(DUNE) | completed | Phase 2 | 126 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT02724540 | Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver | completed | Phase 2 | 162 | Abramson Cancer Center at Penn MedicineOTHER | 4 | Jan 6, 2025 | clinicaltrials |
| NCT05255133 | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment(Liquid-NET) | completed | N/A | 22 | Universiteit AntwerpenOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT03278379 | Avelumab in G2-3 NET(NET-002) | completed | Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04649580 | United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting(PREF-NET) | completed | — | 80 | IpsenINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03034200 | Phase 2 Study of ONC201 in Neuroendocrine Tumors | completed | Phase 2 | 30 | Peter AndersonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06024343 | Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction | completed | N/A | 230 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06557408 | Pancreatic Fistula After Minimally Invasive Enucleation | completed | — | 173 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05448690 | Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas | completed | N/A | 600 | Huashan HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03070301 | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01678664 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors(EVACEL) | completed | Phase 2 | 74 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06570174 | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients | completed | N/A | 60 | Yonsei UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06526481 | Nasoseptal Double Flap Versus Rescue Flap in Endoscopic Transsphenoidal Pituitary Surgery | completed | N/A | 56 | Mansoura UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT01873248 | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | completed | Early Phase 1 | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT01556230 | Prospective Study of Clinically Nonfunctioning Pituitary Adenomas(PAPS) | completed | — | 292 | Columbia UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03288402 | Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients(DIB-NET) | completed | N/A | 346 | University Hospitals Coventry and Warwickshire NHS TrustOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05236829 | Exercise Capacity and Physical Activity Level in Prolactinoma Patients | completed | — | 38 | Hacettepe UniversityOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01398306 | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.(BANN) | completed | — | 40 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01849523 | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study(WIN) | completed | N/A | 20 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02147106 | Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study(VIDEO-NET) | completed | — | 26 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2025source: clinicaltrials